Patient Group Direction
Maternal Pertussis Vaccination Programme - Important Information
From 1 July 2024, ADACEL (Tdap), a non-IPV-containing vaccine, will replace Boostrix-IPV (dTaP/IPV) for the pertussis vaccination in pregnancy programme.
The ADACEL vaccine, manufactured by Sanofi, was licensed for UK use in 2016. The JCVI recognises the importance of vaccinating pregnant women to protect their babies from pertussis and the advice is clear that Boostrix-IPV vaccine should still be given if ADACEL is not available to avoid delays in vaccination.
A bipartite letter providing key information to both commissioners and healthcare professionals responsible for the delivery of the maternal pertussis vaccination programme is available here: https://www.gov.uk/government/publications/prenatal-pertussis-vaccine-change-from-july-2024-letter